A post-marketing surveillance study designed to identify an appropriate patient profile for switching to silodosin in patients with Benign Prostatic Hyperplasia and poor response to existing Alpha-1 Blockers
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Silodosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPLASH
- 08 Feb 2019 New trial record
- 03 Jan 2019 Results published in the Drugs in R and D